Cover Image
市場調查報告書

糖尿病治療藥的全球市場及開發中產品分析 (2015年)

Global Diabetes Drug Market & Pipeline Insight 2015

出版商 KuicK Research 商品編碼 327762
出版日期 內容資訊 英文 1100 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
糖尿病治療藥的全球市場及開發中產品分析 (2015年) Global Diabetes Drug Market & Pipeline Insight 2015
出版日期: 2015年04月03日 內容資訊: 英文 1100 Pages
簡介

隨著全球糖尿病患者的增加,未滿足需求也在急速擴大,而接連創造出莫大的市場機會。投入巨額研究資金的結果,促成了許多新治療藥的開發,相信在短期內將會一一上市。一預測市場規模在今後數年間也將擴大到數倍。

本報告提供全球各國糖尿病治療藥市場趨勢,及開發平台產品的開發情形相關分析,提供糖尿病治療藥的特性和作用機制,整體市場結構·趨勢,開發中產品的目前開發情形,產品單位 (計817產品) 及各臨床實驗階段的詳細開發情形,已上市產品 (計99產品) 銷售情形,各適應症的詳細趨勢,今後的市場方向性等資訊,為您概述為以下內容。

第1章 糖尿病的概要

第2章 糖尿病治療藥的機制

第3章 全球糖尿病治療藥市場概要

  • 目前市場方案
  • 糖尿病治療藥的臨床實驗平台概況

第4章 全球糖尿病治療藥市場動態

  • 良好的市場指標
  • 開發·商業化時的課題

第5章 全球糖尿病治療藥市場未來展望

第6章 糖尿病神經病變的治療藥臨床實驗平台:各企業·Phase (階段) 別

  • 核可前臨床實驗·研究活動情形
  • 已上市醫藥品臨床分析

第7章 糖尿病腎病變的治療藥臨床實驗平台:各企業·Phase別

第8章 糖尿病的治療藥臨床實驗平台:各企業·Phase別

第9章 第一型糖尿病腎病變的治療藥臨床實驗平台:各企業·Phase別

第10章 第二型糖尿病性腎臟病的治療藥臨床實驗平台:各企業·Phase別

第11章 糖尿病性足部潰瘍的治療藥臨床實驗平台:各企業·Phase別

第12章 糖尿病黃斑部水腫的治療藥臨床實驗平台:各企業·Phase別

第13章 糖尿病性胃弱的治療藥臨床實驗平台:各企業·Phase別

第14章 糖尿病視網膜病變的治療藥臨床實驗平台:各企業·Phase別

第15章 前糖尿病狀態的治療藥臨床實驗平台:各企業·Phase別

第16章 糖尿病治療藥的臨床實驗平台:各企業·Phase別

第17章 企業簡介

  • AstraZeneca
  • Boehringer Ingelheim
  • Eli Lily
  • GalaxoSmithKline
  • Johnson & Johnson
  • MannKind Corporation
  • Merck
  • Novartis
  • Pfizer
  • Sanofi

圖表一覽

目錄

Diabetes market is a rapidly growing segment with numerous products at different stages of clinical pipeline and others at different phases of industry life cycle. Disease incidences are escalating rapidly across the globe due to which high unmet demand has been created and pharmaceutical companies are trying to provide efficient medical care to patients. Large patient base and superior technology are some important factors responsible for continuous growth of this market segment across the globe. Significant investments in research and development segment could also be attributed as the main reason behind its growth. As a result, several innovative products are under investigation which would be introduced in market after passing pre described clinical end points and criterias set by medical regulatory authorities. Number of diabetes drugs for treatment is increasing every year due to which their market shares are expected to increase further in coming years.

Diabetes drug delivery is a mature field which provides lots of opportunities to the pharmaceutical companies to market their products. Innovation seems to be the key to success because it is quite mature and without novel functionality it doesn't seem meaningful to enter in such a competitive market segment. Increased investments in research and development segment are expected to introduce competitive products at cost effective prices in short time. It shows that the diabetes drug market segment would be filled with innovative products that would be able to offer better diabetes management to patients. In this way, it could be expected that this market would be able to grow several folds, generate significant revenues and prevent morbidity caused by diabetes.

Several molecules belonging to different classes like carbohydrate digestion inhibitors, sulphonyl urea, insulin sensitizers and others are being screened for their effects on diabetes. They have to prove their candidature by providing better safety and efficacy profiles than existing diabetes drugs. Rigorous clinical trials would be required to prove their pharmacological worthiness for effectively treating diabetes patients. These molecules are known to have cytotoxicity due to which they may have side effects but by modulating its design such problems could be overcome by investigators. On the other hand, these molecules are easy to produce and offer higher cost effectiveness due to which pharmaceutical companies have become interested in their research and development. In coming years, more molecules of these types are expected to enter in global market which would be affordable by large number of patients belonging to different socio-economic groups.

Besides screening of novel molecules, emphasis on discovering different pathways have been given by investigators for developing diabetes drugs with higher safety and efficacy profiles. Insulin pathway is one of the most studied pathways that have been widely targeted by investigators to maintain blood glucose levels. Diabetes drugs that target cellular receptors have been made which works at molecular levels because they have higher control over insulin regulation. Some drug molecules increase the glucose uptake in cells to decrease blood glucose levels. On the other hand, there are diabetes drugs that act on the gastrointestinal tract and prevent the carbohydrate digestion in the body. Investigators have developed many methods to control diabetes and several innovative mechanisms are being studied to come forth with better products. As a result, more products will be launched due to which their market penetration is expected to increase in coming years.

Diabetes Drug Pipeline by Segment in Report:

  • Diabetic Neuropathies
  • Diabetic Nephropathies
  • Diabetes Mellitus
  • Type 1 Diabetes Mellitus
  • Type 2 Diabetes Mellitus
  • Diabetic Foot Ulcer
  • Diabetic Macular Oedema
  • Diabetic Gastroparesis
  • Diabetic Retinopathy
  • Diabetes Insipidus
  • Prediabetic State

"Global Diabetes Drug Market & Pipeline Insight 2015" Report Highlight:

  • Global Diabetes Drug Market Overview
  • Global Diabetic Drug Clinical Pipeline by Company & Phase
  • Global Diabetic Drug Clinical Pipeline: 817 Drugs
  • Majority in Preclinical Phase: 205 Drugs
  • Type 2 Diabetes Mellitus Drugs in Pipeline: 380 Drugs
  • Type 1 Diabetes Mellitus Drugs in Pipeline: 79 Drugs
  • Diabetic Nephropathies Drugs in Pipeline: 41 Drugs
  • Marketed Diabetic Drugs: 99 Drugs

Table of Contents

1. Introduction to Diabetes

2. Diabetes Drug Mechanism

3. Global Diabetes Drug Market Overview

  • 3.1 Current Market Scenario
  • 3.2 Global Diabetes Drug Pipeline Overview

4. Global Diabetes Drug Market Dynamics

  • 4.1 Favorable Market Parameters
  • 4.2 Development & Commercialization Challenges

5. Global Diabetes Drug Market Future Prospects

6. Diabetic Neuropathies Drug Clinical Pipeline by Company & Phase

  • 6.1 Research to till Registered
  • 6.2 Marketed Drug Clinical Insight

7. Diabetic Nephropathies Drug Clinical Pipeline by Company & Phase

  • 7.1 Research to till Registered
  • 7.2 Marketed Drug Clinical Insight

8. Diabetes Mellitus Drug Clinical Pipeline by Company & Phase

  • 8.1 Phase Research to till Registered
  • 8.2 Marketed Drug Clinical Insight

9. Type 1 Diabetes Mellitus Drug Clinical Pipeline by Company & Phase

  • 9.1 Research to till Registered
  • 9.2 Marketed Drug Clinical Insight

10. Type 2 Diabetes Mellitus Drug Clinical Pipeline by Company & Phase

  • 10.1 Research to till Registered
  • 10.2 Marketed Drug Clinical Insight

11. Diabetic Foot Ulcer Drug Clinical Pipeline by Company & Phase

  • 11.1 Research to till Phase-III
  • 11.2 Marketed Drug Clinical Insight

12. Diabetic Macular Oedema Drug Clinical Pipeline by Company & Phase

  • 12.1 Research to till Registered
  • 12.2 Marketed Drug Clinical Insight

13. Diabetic Gastroparesis Drug Clinical Pipeline by Company & Phase

  • 13.1 Preclinical to till Phase-III
  • 13.2 Marketed Drug Clinical Insight

14. Diabetic Retinopathy Drug Clinical Pipeline by Company & Phase

  • 14.1 Research to till Phase-III

15. Prediabetic State Drug Clinical Pipeline by Company & Phase

  • 15.1 Phase-II

16. Diabetes Drug Clinical Pipeline by Company & Phase

  • 16.1 Research to till Registered
  • 16.2 Marketed Drug Clinical Insight

17. Competitive Landscape

  • 17.1 AstraZeneca
  • 17.2 Boehringer Ingelheim
  • 17.3 Eli Lily
  • 17.4 GalaxoSmithKline
  • 17.5 Johnson & Johnson
  • 17.6 MannKind Corporation
  • 17.7 Merck
  • 17.8 Novartis
  • 17.9 Pfizer
  • 17.10 Sanofi

List of Figures and Tables

  • Figure 1-1: Types of Diabetes
  • Figure 1-2: Diseases Associated with Diabetes
  • Figure 1-3: Diabetes Causing Factors
  • Figure 2-1: Function of Insulin
  • Figure 2-2: Mechanism of Metformin
  • Figure 2-3: Mechanism of Pramlintide
  • Figure 2-4: Mechanism of Sulphonylureas
  • Figure 2-5:Mechanism of Alpha-Glycosidase Inhibitors
  • Figure 2-6:Mechanism of Thiazolidinediones
  • Figure 3-1: Global Diabetes Incidences (Million), 2014 & 2035
  • Figure 3-2:Global Distribution of Diabetes Patients (Million), 2014
  • Figure 3-3: Diabetec Neuropathies Pipeline by Phase(%), 2015
  • Figure 3-4: Diabetec Neuropathies Pipeline by Phase(Number), 2015
  • Figure 3-5: Diabetic Nephropathies Pipeline by Phase(%), 2015
  • Figure 3-6: Diabetic Nephropathies Pipeline by Phase(Number), 2015
  • Figure 3-7: Diabetes Mellitus Pipeline by Phase(%), 2015
  • Figure 3-8: Diabetes Mellitus Pipeline by Phase(Number), 2015
  • Figure 3-9: Type 1 Diabetes Mellitus Pipeline by Phase(%), 2015
  • Figure 3-10: Type 1 Diabetes Mellitus Pipeline by Phase(Number), 2015
  • Figure 3-11: Type 2 Diabetes Mellitus Pipeline by Phase(%), 2015
  • Figure 3-12: Type 2 Diabetes Mellitus Pipeline by Phase(Number), 2015
  • Figure 3-13: Diabetic Foot Ulcer Pipeline by Phase(%), 2015
  • Figure 3-14: Diabetic Foot Ulcer Pipeline by Phase(Number), 2015
  • Figure 3-15: Diabetic Macular Oedema Pipeline by Phase(%), 2015
  • Figure 3-16: Diabetic Macular Oedema Pipeline by Phase(Number), 2015
  • Figure 3-17: Diabetic Gastroparesis Pipeline by Phase(%), 2015
  • Figure 3-18: Diabetic Gastroparesis Pipeline by Phase(Number), 2015
  • Figure 3-19: Diabetic Retinopathy Pipeline by Phase(%), 2015
  • Figure 3-20: Diabetic Retinopathy Pipeline by Phase(Number), 2015
  • Figure 3-21: Diabetes Insipidus Pipeline by Phase(%), 2015
  • Figure 3-22: Diabetes Insipidus Pipeline by Phase(Number), 2015
  • Figure 3-23: Multiple Diabetic Pipeline by Phase(%), 2015
  • Figure 3-24: Multiple Diabetic Pipeline by Phase(Number), 2015
  • Figure 4-1: Global Diabetes Drug Market Favorable Parameters
Back to Top